UCB SA UCB
News
BE BOLD: BIMZELX® (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI® (risankizumab-rzaa) at Week 16, with clinical improvements sustained through Week 24
UCB opens applications for 2027 UCB Myasthenia Gravis Scholarship™
UCB advances its digital antibody engineering program with new Cradle collaboration
UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital
UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis
UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

